China’s clinical trial activity in NAFLD increasing
Drug Discovery World
JANUARY 4, 2023
China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM). The post China’s clinical trial activity in NAFLD increasing appeared first on Drug Discovery World (DDW). Not yet a DDW member?
Let's personalize your content